title: [Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy].
abstract: OBJECTIVE
  The presence of epidermal growth factor receptor (EGFR) mutations is predictive of a better response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and initial chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC). The aim of this study is to analyze the association between the EGFR mutations and the outcome of combined chemoradiotherapy in stage III non-squamous NSCLC.
  
  
  METHODS
  Patients with stage III non-squamous NSCLC whose EGFR mutation status had been identified were retrospectively analyzed. The response of 87 patients to combined chemoradiotherapy, the two-year survival rate, and the response of 128 patients to initial chemotherapy were evaluated.
  
  
  RESULTS
  The response rate to combined chemoradiotherapy was 84.6% (33/39) in EGFR mutation-positive patients, significantly higher than the 56.3% (27/48) response rate in EGFR mutation-negative patients (P=0.004). Two-year survival rates were 53.8% and 50% in EGFR mutation-positive and mutation-negative patients, respectively. There was no significant difference in the overall survival for both patient groups. The overall response rate to initial chemotherapy was 34.5% (19/55) in EGFR mutation-positive patients, compared with the 21.9% (16/73) response rate in EGFR mutation-negative patients.
  
  
  CONCLUSIONS
  EGFR mutation-positive status can predict better response to combined chemoradiotherapy, but is not associated with overall survival in patients with stage III non-squamous NSCLC.
authors.affiliation: Department of Radiation Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Fuhai
authors.initials: F
authors.lastname: Li
authors.forename: Hua
authors.initials: H
authors.lastname: Bai
authors.forename: Xia'nan
authors.initials: X
authors.lastname: Li
authors.forename: Meina
authors.initials: M
authors.lastname: Wu
authors.forename: Rong
authors.initials: R
authors.lastname: Yu
authors.forename: Anhui
authors.initials: A
authors.lastname: Shi
authors.forename: Li
authors.initials: L
authors.lastname: Yin
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
authors.forename: Guangying
authors.initials: G
authors.lastname: Zhu
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics* / Q000628:therapy*; D059248:Chemoradiotherapy; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors